Paul M. Polzer

This study develops triazole-based WDR5 inhibitors that show improved brain penetration and antiproliferative activity against glioblastoma CSCs, with synergistic effects when combined with ATAD2 inhibitors.

The paper identifies false positive inhibitors of NSP14 ExoN due to contaminating divalent cations, highlighting challenges in fragment-based drug development for this target.